EQS-News: Drägerwerk AG & Co. KGaA: Dräger on track to meet annual forecast after a solid first half-year
EQS-News: Drägerwerk AG Co. KGaA
/ Key word(s): Half Year Report/Half Year Results
Dräger on track to meet annual forecast after a solid first half-year
Lübeck – Drägerwerk AG Co. KGaA increased its order intake in the first half of 2024 thanks to good overall demand. At around EUR 1,604 million, order intake was around EUR 8 million above the high prior-year figure. Net sales decreased by 0.3 percent (net of currency effects) to EUR 1,520.5 million (6 months 2023: EUR 1,532.4 million) after Dräger had benefited from strong catch-up effects in the same period of the prior year as a result of the noticeable improvement in delivery capacity and a surge in demand for ventilators in China. Earnings before interest and taxes (EBIT) amounted to EUR 55.8 million (6 months 2023: EUR 47.7 million). The EBIT margin amounted to 3.7 percent (6 months 2023: 3.1 percent). In addition to the solid operating business performance, several one-time effects recognized in profit or loss contributed around EUR 20 million to EBIT. These included the sale of a non-core local business activity and the sale of a plot of land that was not required. “Our business performed solidly overall in the first half of 2024,” says Stefan Dräger, Chairman of the Board of Drägerwerk Verwaltungs AG. “Demand for our Technology for Life continued unabated and net sales were almost on a par with the prior year despite the challenging comparative figures. On the earnings side, we continued to improve, making up for the shortfall in earnings from the first quarter in the second quarter.” Continued strong demand in safety business In the safety division, order intake rose by 4.1 percent (net of currency effects) to EUR 704.3 million (6 months 2023: EUR 679.1 million). Almost all product categories recorded higher demand. The biggest growth driver was our occupational health and safety equipment. In the medical division, order intake fell by 1.5 percent (net of currency effects) to EUR 900.1 million (6 months 2023: EUR 917.5 million). This is due in particular to the significantly lower demand for ventilators, which had been supported by an extraordinary surge in demand from China in the same period of the prior year. The significant increase in order volumes for anesthesia, thermoregulation and patient monitoring devices in particular had a positive effect. Safety business continues to grow – medical business burdened by base effects In the medical division, net sales fell by 6.5 percent (net of currency effects) to EUR 846.3 million (6 months 2023: EUR 910.7 million). This was due in particular to the China effect described above. In the same period of the prior year, the division had also benefited from catch-up effects as a result of the noticeable improvement in delivery capacity. Earnings benefit from one-time effects The gross margin rose to 44.8 percent (6 months 2023: 44.0 percent) as a result of the increased share of net sales and the improved gross margin for the safety business. Our functional costs increased by 2.3 percent (net of currency effects). Earnings after taxes amounted to EUR 34.1 million (6 months 2023: EUR 28.6 million). Business development in the second quarter Dräger’s net sales increased by 2.0 percent (net of currency effects) to EUR 784.7 million (Q2 2023: EUR 771.3 million). The gross margin increased to 44.3 percent (Q2 2023: 43.1 percent). EBIT amounted to EUR 40.7 million (Q2 2023: EUR 18.7 million). The EBIT margin amounted to 5.2 percent (Q2 2023: 2.4 percent). Annual forecast confirmed “Due to the continued moderate demand in the medical business, we now tend to expect net sales growth in the lower half of the forecast range. However, we have become more optimistic with regard to our profitability. We now believe that an EBIT margin in the upper half of the forecast range is more likely,” says Stefan Dräger. Further information is available in the financial report at www.draeger.com. Disclaimer
25.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | Drägerwerk AG Co. KGaA |
Moislinger Allee 53-55 | |
23558 Lübeck | |
Germany | |
Phone: | +49 (0)451 882-0 |
Fax: | +49 (0)451 882-2080 |
E-mail: | [email protected] |
Internet: | www.draeger.com |
ISIN: | DE0005550602, DE 000 555 063 6, DE 000 555 071 9 |
WKN: | 555060, 555063 Vorzüge, 555071 Genussschein D |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Stuttgart, Tradegate Exchange |
EQS News ID: | 1953403 |
End of News | EQS News Service |
|
1953403 25.07.2024 CET/CEST
Drägerwerk AG & Co. KGaA ST Aktie
Leichtes Buy-Übergewicht bei der Drägerwerk AG & Co. KGaA ST Aktie mit 3 zu 0 Einschätzungen.
Eine Steigerung von über 20% ist für Drägerwerk AG & Co. KGaA ST möglich, angesichts eines Kursziels von 66 € gegenüber 44.1 €.